Aibotics, Inc. (AIBT) income statement
AIBTOTCMedicinal Chemicals & Botanical ProductsFiscal year ends December 31
$0.00+0.00 (+42.86%)
Close on Oct 19, 2026Market cap –P/E –Yield –
Aibotics, Inc. financial ratios
See a number that looks wrong?
Close on Oct 19, 2026Market cap –P/E –Yield –
See a number that looks wrong?
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Margins | |||||||||
| Gross margin | 100.0% | – | – | – | – | – | – | – | – |
| Operating margin | -84,501.7% | – | – | – | – | – | – | – | – |
| Pre-tax margin | -101,500.3% | – | – | – | – | – | – | – | – |
| Net profit margin | -101,500.3% | – | – | – | – | – | – | – | – |
| Returns on capital | |||||||||
| Return on equity | 0.00% | 0.00% | 80.9% | 622.4% | -28,729.7% | 188.9% | – | – | – |
| Return on assets | -190.1% | -100.5% | -90.6% | -315.2% | -744.3% | -2.4% | – | – | – |
| Return on tangible assets | -190.1% | -326.4% | -90.6% | -315.2% | -744.3% | -2.4% | – | – | – |
| Return on capital employed | 50.4% | 60.3% | 51.3% | -1,163.3% | -1,271.5% | -3.7% | -38.8% | -28.8% | – |
| NOPAT | -$1.46M | -$1.29M | -$487.21K | -$1.37M | -$3.94M | -$11.24K | -$198.86K | -$147.00K | – |
| Cash flow quality | |||||||||
| OCF / Sales | -20,991.3% | – | – | – | – | – | – | – | – |
| OCF / Net income | 0.21 | 0.14 | 0.09 | 0.25 | 0.05 | 0.89 | – | – | – |
| FCF / OCF | – | – | – | 100.0% | 101.2% | 100.0% | – | – | – |
| FCF / Net income | – | – | – | 0.25 | 0.05 | 0.89 | – | – | – |
| Unlevered free cash flow | – | – | – | $25.41K | -$125.21K | -$14.25K | – | – | – |
| Levered free cash flow | – | – | – | -$656.62K | -$238.23K | -$14.25K | – | – | – |
| Efficiency | |||||||||
| Asset turnover | 0.00 | 0.00 | – | – | – | – | 0.00 | 0.00 | – |
| Fixed asset turnover | – | 0.00 | – | – | – | – | 0.00 | 0.00 | – |
| Receivables turnover | – | – | – | – | – | – | 0.00 | – | – |
| Payables turnover | – | – | – | – | – | – | 0.00 | 0.00 | – |
| Inventory turnover | – | – | – | – | – | – | – | 0.00 | – |
| CapEx to OCF | – | – | – | -0.00% | -1.2% | -0.00% | – | – | – |
| Liquidity | |||||||||
| Current ratio | 0.06 | 0.04 | 0.07 | 0.50 | 2.13 | 55.48 | 2.16 | 1.76 | – |
| Quick ratio | 0.06 | 0.04 | 0.07 | 0.50 | 2.13 | 55.48 | 2.16 | 1.74 | – |
| Cash ratio | 0.05 | 0.04 | 0.07 | 0.50 | 2.13 | 55.48 | 0.00 | 0.72 | – |
| Working capital | -$4.52M | -$4.67M | -$3.97M | -$378.61K | $673.15K | $108.75K | $651.36K | $646.23K | – |
| Net current asset value | -$4.56M | -$4.67M | -$3.97M | -$892.84K | $49.52K | -$16.25K | $651.36K | $646.23K | – |
| Leverage | |||||||||
| Assets to equity | -0.22 | -0.43 | -1.09 | -0.43 | 24.41 | -6.82 | -1,687.68 | 2.32 | – |
| Intangibles to total assets | – | 87.3% | – | – | – | – | – | – | – |
| Interest coverage | |||||||||
| EBIT / Interest expense | -8.13 | -7.66 | -1.09 | -2.01 | -34.86 | – | -31,464.75 | -1,563.65 | – |
| Per share | |||||||||
| Revenue per share | 0.0000 | 0.00 | – | – | – | – | 0.00 | 0.00 | – |
| EPS (basic) | – | – | – | – | – | – | 0.00 | 0.00 | – |
| EPS (diluted) | – | – | – | – | – | – | 0.00 | 0.00 | – |
| Book value per share | -0.0081 | -0.08 | -0.14 | -0.06 | 0.0037 | -0.0013 | -0.0001 | 0.05 | – |
| Tangible book value per share | -0.0081 | -0.12 | -0.14 | -0.06 | 0.0037 | -0.0013 | -0.0001 | 0.05 | – |
| Cash per share | 0.0005 | 0.0046 | 0.02 | 0.03 | 0.09 | 0.0086 | 0.00 | 0.05 | – |
| Operating cash flow per share | -0.0009 | -0.0065 | -0.0072 | -0.04 | -0.02 | -0.0011 | 0.0079 | -0.0055 | – |
| Free cash flow per share | – | – | – | -0.04 | -0.02 | -0.0011 | – | – | – |
| CapEx per share | – | – | – | 0.00 | 0.0002 | 0.00 | – | – | – |
| Valuation at period end | |||||||||
| Market cap | $797.23K | $93.74K | $238.35K | $2.62M | $31.25M | $10.34M | $2.09M | – | – |
| Enterprise value | $566.76K | -$108.62K | -$78.64K | $2.18M | $30.30M | $10.22M | $1.33M | – | – |
| P/S | 365x | – | – | – | – | – | – | – | – |
| P/B | -0.2x | -0.0x | -0.1x | -2.9x | 601x | -636x | -2,899x | – | – |
| P/TBV | -0.2x | -0.0x | -0.1x | -2.9x | 601x | -636x | -2,899x | – | – |
| P/Gross profit | 365x | – | – | – | – | – | – | – | – |
| P/OCF | -1.7x | -0.4x | -2.2x | -4.0x | -133x | -725x | 21.2x | – | – |
| EV/Sales | 260x | – | – | – | – | – | – | – | – |
| EV/Gross profit | 260x | – | – | – | – | – | – | – | – |
| EV/EBIT | – | 0.1x | 0.1x | – | – | – | – | – | – |
| EV/OCF | -1.2x | 0.4x | 0.7x | -3.3x | -129x | -717x | 13.5x | – | – |
| Earnings yield | -277.9% | -1,971.8% | -495.6% | -99.7% | -16.4% | -0.16% | – | – | – |
| FCF yield | – | – | – | -25.1% | -0.76% | -0.14% | – | – | – |
| Per employee | |||||||||
| Total employees | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Revenue per employee | $2.18K | $0 | – | – | – | – | $0 | $0 | – |
| Gross profit per employee | $2.18K | $0 | – | – | – | – | $0 | $0 | – |
| Operating profit per employee | -$1.84M | -$1.63M | -$616.72K | -$1.74M | -$4.99M | -$14.22K | -$251.72K | -$186.07K | – |
| Net income per employee | -$2.22M | -$1.85M | -$1.18M | -$2.61M | -$5.14M | -$16.03K | – | – | – |
| Free cash flow per employee | – | – | – | -$656.62K | -$238.23K | -$14.25K | – | – | – |
| Growth | |||||||||
| EBIT 1Y growth | -12.8% | -165.1% | 64.5% | 65.2% | -34,962.7% | 94.3% | -35.3% | – | – |
| Net income 1Y growth | -19.9% | -56.5% | 54.8% | 49.2% | -31,958.1% | – | – | – | – |
| Operating cash flow 1Y growth | -76.9% | -142.6% | 83.7% | -178.8% | -1,552.2% | -114.4% | 244.0% | – | – |
| Free cash flow 1Y growth | – | – | – | -175.6% | -1,571.4% | – | – | – | – |
| CapEx 1Y growth | – | – | – | -100.0% | – | – | – | – | – |
| Total assets 1Y growth | -40.0% | -34.4% | 472.9% | -69.5% | 1,046.8% | -90.9% | -19.0% | – | – |
| Total assets 3Y CAGR | 31.2% | 4.7% | 171.6% | -31.7% | -5.4% | – | – | – | – |
| Total assets 5Y CAGR | 51.2% | 3.7% | 8.2% | – | – | – | – | – | – |
| Total equity 1Y growth | -16.7% | -67.4% | -127.6% | -1,813.4% | 420.1% | -2,156.8% | -100.1% | 13.1% | – |
| Total equity 3Y CAGR | – | – | – | – | -56.8% | – | – | – | – |
Every figure here is calculated from standardized financial statements — hover a row name for the formula — not reported by the company. Valuation multiples use the closing price at the end of that period, not today's price.